mTOR Signaling Confers Resistance to Targeted Cancer Drugs

Cancer is a complex disease and a leading cause of death worldwide. Extensive research over decades has led to the development of therapies that target cancer-specific signaling pathways. However, the clinical benefits of such drugs are at best transient due to tumors displaying intrinsic or adaptive resistance. The underlying compensatory pathways that allow cancer cells to circumvent a drug blockade are poorly understood. We review here recent studies suggesting that mammalian TOR (mTOR) signaling is a major compensatory pathway conferring resistance to many cancer drugs.

Read the full abstract on PubMed →

Guri, Y., et al. (2016). mTOR Signaling Confers Resistance to Targeted Cancer Drugs. Trends in cancer. https://doi.org/10.1016/j.trecan.2016.10.006

@article{GUR2016,
  author       = {Guri, Y. and Hall, M. N. and others},
  title        = {{mTOR Signaling Confers Resistance to Targeted Cancer Drugs}},
  journal      = {Trends in cancer},
  year         = {2016},
  doi          = {10.1016/j.trecan.2016.10.006},
  note         = {PMID: 28741507},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record GUR2016) [Data set]. https://mtor-atlas.org/study/GUR2016/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_GUR2016,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record GUR2016},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/GUR2016/},
  doi          = {10.5281/zenodo.22059963}
}